Lv7
5010 积分 2023-10-08 加入
A phase 1/2 study of ubamatamab (REGN4018): low-grade serous ovarian cancer expansion cohort
17天前
已关闭
Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
21天前
已完结
Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer
21天前
已完结
Targeting MUC16 suppresses malignant progression and chemoresistance in large-duct type intrahepatic cholangiocarcinoma
25天前
已完结
Recent advances in function-enhanced antibody-drug conjugates: Antibody optimization and payload combination
1个月前
已完结
The next generation of antibody–drug conjugates
1个月前
已完结
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer
1个月前
已完结
Antibody-drug conjugates-related interstitial lung diseases: data mining of the FAERS database
1个月前
已完结
Methods and clinical biomarker discovery for targeted proteomics using Olink technology
2个月前
已完结
Biomarkers for Antibody–Drug Conjugates in Solid Tumors
3个月前
已完结
The Theory and Practice of Genome Sequence Assembly
皖公网安备34019202002308
